Marketing application for pegcetacoplan for paroxysmal nocturnal hemoglobinuria (PNH) is under review by the U.S. Food and Drug Administration (FDA) with a PDUFA target action
Post hoc analysis showed a 46% decrease in mean lesion growth in eight patients with bilateral GA comparing treated eye vs. untreated fellow eye at
New UK company backed by Epidarex Capital emerges from stealth Cambridge, UK, March 23, 2021 – Dunad Therapeutics (“Dunad”) emerges today to develop next-generation small
Pegcetacoplan, an investigational targeted C3 therapy for serious, complement-driven diseases, demonstrated superiority to eculizumab with a statistically significant improvement in hemoglobin levels and showed improvements
Data published in Ophthalmology and the American Journal of Ophthalmology underscore the potential of pegcetacoplan, an investigational targeted C3 therapy, for geographic atrophy WALTHAM, Mass., March 10, 2021 (GLOBE
Leeds, UK, 5 February 2021: LUNAC Therapeutics (LUNAC), a UK based drug discovery company focused on the development of advanced life-saving anticoagulants, has been named
CHARLOTTESVILLE, Va. —Slate Bio, Inc., announced today the closing of a $1.75 million venture financing. Epidarex Capital led the investment round with participation from the UVA
Oxford, UK, 7th January 2020 – Theolytics, a UK biotech harnessing viruses to combat cancer, today announced the closing of a US $7 million (UK
Strengthens senior leadership team with appointments of Donald Johns, M.D., as Chief Medical Officer and Katina Dorton, J.D., MBA, as Chief Financial Officer CAMBRIDGE, UK, BOSTON
Treatment with pegcetacoplan resulted in a sustained improvement in hemoglobin with a mean increase from baseline of 2.7 g/dL at Week 48, which is equal